Patents by Inventor Mark Leslie Smythe

Mark Leslie Smythe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240066131
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 28, 2021
    Publication date: February 29, 2024
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas BOURNE, Ashok BHANDARI, Jie ZHANG, Brian Troy FREDERICK, Mark Leslie SMYTHE
  • Publication number: 20240018189
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 18, 2024
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas BOURNE, Ashok BHANDARI, Jie ZHANG, Brian Troy FREDERICK, Mark Leslie SMYTHE
  • Patent number: 11807674
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: November 7, 2023
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Publication number: 20230295259
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: July 28, 2021
    Publication date: September 21, 2023
    Inventors: Gregory Thomas Bourne, Ashok Bhandari, Jie Zhang, Brian Troy Frederick, Mark Leslie Smythe, Roopa Taranath
  • Patent number: 11753443
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: September 12, 2023
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas Bourne, Ashok Bhandari, Brian Troy Frederick, Jie Zhang, Adam Stephenson, Mark Leslie Smythe, Roopa Taranath, David Liu
  • Publication number: 20220348626
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: November 16, 2020
    Publication date: November 3, 2022
    Inventors: Mark Leslie SMYTHE, Gregory Thomas BOURNE, Simone VINK, Brian Troy FREDERICK, Praveen MADALA, Anne Pernille TOFTENG SHELTON, Jacob Ulrik FOG
  • Patent number: 11472842
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: October 18, 2022
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Thomas Bourne, Mark Leslie Smythe, Brian Troy Frederick, Ashok Bhandari
  • Publication number: 20210147483
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: October 1, 2020
    Publication date: May 20, 2021
    Inventors: Gregory Thomas Bourne, Mark Leslie Smythe, Brian Troy Frederick, Ashok Bhandari
  • Publication number: 20200361992
    Abstract: The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: February 8, 2019
    Publication date: November 19, 2020
    Inventors: Gregory Thomas BOURNE, Ashok BHANDARI, Brian Troy FREDERICK, Jie ZHANG, Adam STEPHENSON, Mark Leslie SMYTHE, Roopa TARANATH, David LIU
  • Publication number: 20200017566
    Abstract: The present invention provides novel hepcidin analogues, and related methods of using these hepcidin analogues to treat or prevent a variety of diseases and disorders, including iron overload diseases such as hereditary hemochromatosis, iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: June 12, 2019
    Publication date: January 16, 2020
    Inventors: Gregory Thomas BOURNE, Mark Leslie SMYTHE, Brian Troy FREDERICK, Simone VINK
  • Patent number: 10501515
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 10, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Patent number: 10442846
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 15, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Publication number: 20190264197
    Abstract: Provided herein are libraries of structurally diverse disulfide-rich peptides (DRPs) and related methods of screening these libraries to identify DRPs that bind to a desired target.
    Type: Application
    Filed: July 27, 2017
    Publication date: August 29, 2019
    Inventors: David BARKAN, Tran Trung TRAN, Mark Leslie SMYTHE
  • Publication number: 20190185535
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: July 17, 2018
    Publication date: June 20, 2019
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Publication number: 20190185536
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 20, 2019
    Inventors: Mark Leslie SMYTHE, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Publication number: 20190002503
    Abstract: The present invention provides hepcidin analogues with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: December 29, 2016
    Publication date: January 3, 2019
    Inventors: Gregory Thomas Bourne, Mark Leslie Smythe, Brian Troy Frederick, Ashok Bhandari
  • Patent number: 10030061
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 24, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Publication number: 20180100004
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: September 29, 2017
    Publication date: April 12, 2018
    Inventors: Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Publication number: 20180086811
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: November 30, 2017
    Publication date: March 29, 2018
    Inventors: Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Patent number: 9822157
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 21, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog